• Loading stock data…

Humacyte to Present at Upcoming Investor Conferences in March

Last Updated on March 1, 2022 by Chris Stang

DURHAM, N.C., March 01, 2022 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced that Laura Niklason, M.D., Ph.D., Chief Executive Officer, and Dale Sander, Chief Financial Officer, will represent Humacyte at the following investor conferences in March.

Cowen’s 42nd Annual Health Care Conference (March 7-9, 2022)Format:
Virtual Fireside Chat
Date:Tuesday, March 8, 2022 Time:2:10 – 2:20 p.m. EST Oppenheimer’s 32nd Annual Healthcare Conference (March 15-16, 2022)Format:
Virtual Corporate Presentation
Date:Wednesday, March 16, 2022Time:12:40 – 1:10 p.m. EDT

The webcasts will be available for replay for at least 30 days following the presentations at https://investors.humacyte.com/news-events/events-and-presentations.

About Humacyte
Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte’s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte’s 6mm HAVs for AV access for performing hemodialysis was the first product candidate to receive the FDA’s Regenerative Medicine Advanced Therapy (RMAT) expedited review designation, and the HAV technology received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense. For more information, visit www.Humacyte.com.

Humacyte Investor Contact:
Joyce Allaire
LifeSci Advisors LLC

Humacyte Media Contact:
Heather Anderson
6 Degrees

Print Friendly, PDF & Email
Spread the word

Reader Interactions

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Generated by Feedzy
%d bloggers like this: